Early-stage pharma developer Sareum Holdings (AIM:SAR) is making good progress on its pipeline of projects, justifying the share price rise increases earlier this year.
With Covid spreading damage particularly hard in the UK in the early months of 2021 shares rocketed to 8.85 pence in August – from 220 pence at the end of 2020 – as investors' focus zeroed in on the company’s research on a molecule that could be used to treat breathing complications caused by the virus.
Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.
Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.
Free 28 day trial. Cancel anytime.
Log In or Sign Up to Armchair Trader+Already a member? Log in here:
Not a member? Sign up now or see the membership benefits
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.